All Oncology articles – Page 11
-
ArticleLeveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
-
NewsReprogramming immune-suppressive macrophages in tumours
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
-
ArticleImproving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
-
WebinarImmunotherapy advancements: transforming cancer treatment
In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint ...
-
NewsBreast cancer genetic variants in women of African ancestry
Researchers identified variants in three loci that were associated with risk of triple-negative breast cancer.
-
NewsNanoparticle targets primary tumours and brain metastases
A specialised drug-loaded nanoparticle, which can cross the blood-brain barrier, shrunk both breast tumours and breast cancer cells.
-
NewsAssociations of AML MRD levels with posttransplant clinical outcomes
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
-
ArticleBiomarker identification in the realm of rare diseases
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
-
ArticleUnlocking the potential of antibody drug conjugates
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several ...
-
NewsFirst animal model for Kaposi sarcoma developed
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
-
NewsTargeting RAS to overcome FLT3 AML drug resistance
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
-
NewsNew screening method for HPV-positive head and neck cancer
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
-
NewsElucidating the mechanism that initiates cancer cachexia
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
-
NewsMelanoma tumours produce altBRAFs by genomic deletions
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
-
News
B-ALL: combination therapy effectively controls high-risk subtypes
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
-
Article
HIF inhibition: a potential therapeutic approach for cancers
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
-
News
MUTYH variants implicated in a broader range of cancers
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
-
News
Study concludes that most aspects of aging relate to gene length
New findings about how long genes become less active with age could impact treatments for neurodegeneration, among other conditions.
-
NewsThe first core regulatory circuit identified for ALCL
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
-
NewsTargeting Inc-HLX-2-7 shrinks group 3 medulloblastoma tumours
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.